What is CAR-T therapy and how does it treat lymphoma?

CAR-T therapy is a personalized immunotherapy where a patient's T-cells are genetically engineered to recognize and attack cancer cells, then infused back into the body.

What are the risks associated with CAR-T treatment for lymphoma?

CAR-T therapy can have side effects, including neurotoxicity, and patients typically require hospitalization for one to two weeks after the infusion.

What is diffuse large B-cell lymphoma and how common is it?

Diffuse large B-cell lymphoma is a common and fast-growing type of blood cancer, with about 25,000 cases diagnosed annually in the United States.

Home / Health / Cancer Survivor's Pac-Man Battle Against Lymphoma

Cancer Survivor's Pac-Man Battle Against Lymphoma

7 Mar

•

Summary

Lymphoma recurred in brain, changing prognosis to dismal.
CAR-T therapy, a personalized immunotherapy, offered a chance.
Patient achieved complete remission after treatment.

Cancer Survivor's Pac-Man Battle Against Lymphoma

A New Jersey woman diagnosed with diffuse large B-cell lymphoma experienced a recurrence of the aggressive blood cancer in her brain, leading to a dismal prognosis. Initial chemotherapy provided only temporary relief, prompting her care team to consider a personalized immunotherapy called CAR-T. This innovative treatment involves genetically engineering a patient's own T-cells to target and destroy cancer cells.

In January 2025, she underwent the CAR-T infusion, visualizing the process like a video game where her cells would "Pac-Man" the cancer. The treatment proved remarkably successful with no side effects, leading to her discharge from the hospital within two weeks.